Takeda Settles Intuniv Pay for Delay Claims for $1.85 Mln
“Takeda Pharmaceutical Co has agreed to pay $1.85 million to settle claims by consumers that its predecessor Shire PLC delayed the launch of a generic version of its ADHD drug Intuniv through an illegal settlement with generic drugmaker Actavis. The consumers, known as indirect purchasers because,” reports Brendan Pierson in Reuters.
“They bought brand-name or generic Intuniv through intermediaries, asked U.S. District Judge Allison Burroughs to approve the deal on Friday. The indirect purchasers last year settled for $1.1 million with Teva Pharmaceutical Industries Ltd, which bought Actavis in 2015. Conlee Whiteley of Kanner & Whiteley, a lawyer for the indirect.”